tradingkey.logo
tradingkey.logo
Search

Alterity Therapeutics Ltd

ATHE
Add to Watchlist
4.415USD
-0.070-1.56%
Close 07-31 16:00ETQuotes delayed by 15 min
67.16MMarket Cap
LossP/E TTM

ATHE Income Statement

You can find the annual or quarterly income statement of Alterity Therapeutics Ltd here for insights into the performance and operational efficiency of Alterity Therapeutics Ltd.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025H1
FY2024H2
FY2024H1
FY2023H2
FY2023H1
FY2022H1
FY2021H2
FY2021H1
FY2020H2
FY2020H1
FY2019H2
FY2019H1
FY2018H2
FY2018H1
FY2017H2
FY2017H1
FY2016H2
FY2016H1
FY2015H2
FY2015H1
FY2014H2
FY2014H1
FY2013H1
FY2012H2
FY2012H1
Total revenue
-4.87%73.51K
2791.60%98.78K
913.80%77.27K
--3.42K
671.95%7.62K
-79.15%987.32
455.64%10.89K
-51.04%4.74K
-93.42%1.96K
-79.86%9.67K
-54.01%29.78K
-47.36%48.03K
44.43%64.76K
66.28%91.25K
-6.36%44.84K
-1.75%54.88K
-27.33%47.89K
-32.02%55.86K
-58.61%65.89K
-52.93%82.17K
--159.18K
324.70%174.55K
-63.83%41.10K
--78.80K
--113.64K
Operating expenses
4.58%5.82M
89.36%9.95M
-22.89%5.57M
--5.25M
-2.90%7.22M
6.67%7.43M
84.29%7.61M
33.30%6.97M
-39.77%4.13M
-10.09%5.23M
30.13%6.86M
66.47%5.81M
75.55%5.27M
-23.36%3.49M
-36.40%3.00M
-10.42%4.56M
-34.66%4.72M
-27.87%5.09M
-29.78%7.23M
-19.38%7.05M
--10.29M
29.87%8.75M
52.90%6.74M
--3.68M
--4.41M
R&D expenses
-9.03%3.78M
120.31%8.09M
-20.18%4.15M
--3.67M
5.16%5.20M
17.83%4.95M
74.75%4.99M
6.70%4.20M
-42.96%2.86M
-7.74%3.93M
47.27%5.01M
139.42%4.26M
141.66%3.40M
-38.30%1.78M
-58.86%1.41M
-30.85%2.89M
-45.24%3.42M
-29.35%4.17M
-21.90%6.25M
-21.92%5.91M
--8.00M
32.57%7.56M
67.78%5.71M
--2.88M
--3.40M
Depreciation, depletion, and amortization
-0.62%47.94K
37.28%48.47K
44.05%48.24K
--35.31K
45.19%33.49K
-10.44%23.06K
-15.50%30.63K
-34.24%25.75K
241.76%36.25K
268.69%39.16K
10.30%10.61K
46.25%10.62K
18.05%9.62K
-8.28%7.26K
10.62%8.15K
-14.12%7.92K
-35.89%7.36K
-38.52%9.22K
20.66%11.49K
36.12%15.00K
--9.52K
-15.39%11.02K
20.37%13.02K
--9.41K
--10.82K
Other operating expenses
1475.53%37.34K
-59.87%1.06K
-86.12%2.37K
--2.64K
3643.03%17.08K
3057.20%456.36
-36.51%1.70K
-99.95%14.45
-96.38%2.68K
34.77%27.47K
272.50%74.00K
-77.01%20.38K
-226.29%-42.90K
45.38%88.65K
102.37%33.97K
-90.47%60.98K
-331.73%-1.43M
-13.54%640.17K
-53.18%619.25K
10.95%740.39K
--1.32M
-0.97%667.34K
5.37%673.85K
--502.10K
--639.50K
Operating profit
-4.71%-5.75M
-87.60%-9.85M
23.88%-5.49M
---5.25M
2.99%-7.21M
-6.73%-7.43M
-84.11%-7.60M
-33.45%-6.96M
39.54%-4.13M
9.51%-5.22M
-31.18%-6.83M
-69.53%-5.77M
-76.02%-5.21M
24.45%-3.40M
36.71%-2.96M
10.52%-4.50M
34.73%-4.67M
27.82%-5.03M
29.32%-7.16M
18.69%-6.97M
---10.13M
-28.05%-8.57M
-55.99%-6.69M
---3.61M
---4.29M
Net non-operating interest income (expenses)
Non-operating interest expense
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
----
----
----
----
----
----
Gains from sale of securities
-1925.00%-45.24K
-44.84%174.20K
-100.74%-2.23K
--315.84K
-66.18%301.46K
244.71%891.33K
217.55%427.89K
-804.04%-615.93K
27.41%134.75K
-39.35%87.48K
-59.66%105.76K
130.31%144.24K
130.09%262.16K
-227.40%-475.82K
-157.38%-871.12K
-60.80%373.50K
-129.51%-338.46K
-67.02%952.81K
227.75%1.15M
1231.27%2.89M
---897.67K
376.18%217.01K
-987.32%-78.57K
--38.54K
--8.86K
Special income (expenses)
----
----
----
----
----
-100.00%0.00
0.02%80.60K
--29.68K
--80.58K
----
----
----
----
----
----
----
-115.02%-8.42K
-36.20%8.30K
-78.32%56.04K
104.51%13.01K
--258.49K
-266.03%-288.27K
-433.19%-78.75K
--10.53K
--23.64K
Other non-operating income (expenses)
-309.25%-6.38K
-99.68%3.30K
-99.81%3.05K
--1.03M
867.92%1.60M
--165.10K
--164.36K
----
----
----
----
----
----
----
----
-100.00%0.00
-100.04%-37.38
-99.96%36.84
-98.45%90.48K
-92.55%100.15K
--5.83M
-42.86%1.34M
199.29%2.35M
--1.63M
--786.22K
Income before tax
-5.67%-5.80M
-147.97%-9.67M
-3.33%-5.49M
---3.90M
16.71%-5.31M
15.55%-6.38M
-77.05%-6.93M
-47.16%-7.55M
41.79%-3.91M
8.74%-5.13M
-35.99%-6.72M
-45.00%-5.62M
-29.13%-4.94M
6.09%-3.88M
23.73%-3.83M
-1.43%-4.13M
14.43%-5.02M
-2.56%-4.07M
-18.87%-5.87M
45.63%-3.97M
---4.94M
-62.25%-7.30M
-29.54%-4.50M
---1.93M
---3.47M
Income tax
14.50%-1.06M
-361478.80%-1.36M
-1882.41%-1.24M
--377.60
104.46%69.59K
-14.63%-1.56M
-241.94%-1.73M
-7.20%-1.36M
168.33%1.22M
27.70%-1.27M
-30.98%-1.78M
-65.78%-1.76M
-51.56%-1.36M
23.15%-1.06M
37.95%-898.02K
31.34%-1.38M
35.52%-1.45M
29.72%-2.01M
---2.24M
---2.86M
--0.00
--0.00
--0.00
--0.00
--0.00
Income after tax
-11.56%-4.74M
-112.96%-8.31M
21.06%-4.25M
---3.90M
-11.73%-5.38M
22.19%-4.81M
-1.34%-5.20M
-60.30%-6.19M
-3.87%-5.13M
0.13%-3.86M
-37.90%-4.94M
-37.19%-3.87M
-22.26%-3.58M
-2.46%-2.82M
17.97%-2.93M
-33.34%-2.75M
1.36%-3.57M
-85.48%-2.06M
26.61%-3.62M
84.77%-1.11M
---4.94M
-62.25%-7.30M
-29.54%-4.50M
---1.93M
---3.47M
Net income from continuous operations
-11.56%-4.74M
-112.96%-8.31M
21.06%-4.25M
---3.90M
-11.73%-5.38M
22.19%-4.81M
-1.34%-5.20M
-60.30%-6.19M
-3.87%-5.13M
0.13%-3.86M
-37.90%-4.94M
-37.19%-3.87M
-22.26%-3.58M
-2.46%-2.82M
17.97%-2.93M
-33.34%-2.75M
1.36%-3.57M
-85.48%-2.06M
26.61%-3.62M
84.77%-1.11M
---4.94M
-62.25%-7.30M
-29.54%-4.50M
---1.93M
---3.47M
Net income attributable to controlling interests
-11.56%-4.74M
-112.96%-8.31M
21.06%-4.25M
---3.90M
-11.73%-5.38M
22.19%-4.81M
-1.34%-5.20M
-60.30%-6.19M
-3.87%-5.13M
0.13%-3.86M
-37.90%-4.94M
-37.19%-3.87M
-22.26%-3.58M
-2.46%-2.82M
17.97%-2.93M
-33.34%-2.75M
1.36%-3.57M
-85.48%-2.06M
26.61%-3.62M
84.77%-1.11M
---4.94M
-62.25%-7.30M
-29.54%-4.50M
---1.93M
---3.47M
Net income attributable to common shareholders
-11.56%-4.74M
-112.96%-8.31M
21.06%-4.25M
---3.90M
-11.73%-5.38M
22.19%-4.81M
-1.34%-5.20M
-60.30%-6.19M
-3.87%-5.13M
0.13%-3.86M
-37.90%-4.94M
-37.19%-3.87M
-22.26%-3.58M
-2.46%-2.82M
17.97%-2.93M
-33.34%-2.75M
1.36%-3.57M
-85.48%-2.06M
26.61%-3.62M
84.77%-1.11M
---4.94M
-62.25%-7.30M
-29.54%-4.50M
---1.93M
---3.47M
Basic earnings per share
45.88%0.00
-8.12%0.00
23.77%0.00
--0.00
-11.50%0.00
57.26%0.00
54.94%0.00
-5.17%0.00
21.99%-0.01
37.94%0.00
-6.09%-0.01
-35.80%-0.01
-22.59%-0.01
-2.52%-0.01
17.94%-0.01
-33.42%-0.01
4.56%-0.01
-70.04%0.00
35.63%-0.01
87.47%0.00
---0.01
-28.44%-0.02
-13.53%-0.01
---0.01
---0.01
Diluted earnings per share
45.88%0.00
-8.12%0.00
23.77%0.00
--0.00
-11.50%0.00
57.26%0.00
54.94%0.00
-5.17%0.00
21.99%-0.01
37.94%0.00
-6.09%-0.01
-35.80%-0.01
-22.59%-0.01
-2.52%-0.01
17.94%-0.01
-33.42%-0.01
4.56%-0.01
-70.04%0.00
35.63%-0.01
87.47%0.00
---0.01
-28.44%-0.02
-13.53%-0.01
---0.01
---0.01
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Alterity Therapeutics Ltd's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing ATHE stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Alterity Therapeutics Ltd's revenue at year end?

Alterity Therapeutics Ltd reported 288.77K in revenue for fiscal year 2025, up from 175.92K in the previous year.

How much revenue did Alterity Therapeutics Ltd report in the most recent quarter?

Alterity Therapeutics Ltd reported 73.51K in revenue for the most recent quarter, an increase of -4.87% year over year.

What was Alterity Therapeutics Ltd's net income for the year?

Alterity Therapeutics Ltd posted -7.86M in net income for fiscal year 2025.

How much net income did Alterity Therapeutics Ltd post in the last quarter?

Alterity Therapeutics Ltd reported -4.74M in net income for the latest quarter。

What was Alterity Therapeutics Ltd's annual operating profit?

Alterity Therapeutics Ltd's operating income was -12.72M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.